Lutein protects dopaminergic neurons against MPTP-induced apoptotic death and motor dysfunction by ameliorating mitochondrial disruption and oxidative stress

Nutritional Neuroscience

Volumn 19, Issue 6, 2016, Pages 237-246

  Nataraj, Jagatheesan ^a   Manivasagam, Thamilarasan ^a   Justin Thenmozhi, Arokiasamy ^a   Essa, Musthafa Mohammed ^b  

^a ANNAMALAI UNIVERSITY   (India)

^b SULTAN QABOOS UNIVERSITY   (Oman)

Author keywords

Apoptosis and lutein; Mitochondrial dysfunction; Oxidative stress; Parkinson s disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CASPASE 3; CASPASE 8; CASPASE 9; CATALASE; DOPAMINE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; XANTHOPHYLL; ANTIPARKINSON AGENT; APOPTOSIS REGULATORY PROTEIN; BIOLOGICAL MARKER; NERVE PROTEIN; NEUROPROTECTIVE AGENT;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; EXPERIMENTAL BEHAVIORAL TEST; EXPERIMENTAL CATALEPSY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPID PEROXIDATION; MALE; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; ADVERSE EFFECTS; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; COMPARATIVE STUDY; DIETARY SUPPLEMENT; DRUG EFFECTS; METABOLISM; MITOCHONDRION; MOTOR ACTIVITY; MPTP POISONING; PARKINSON DISEASE; PATHOPHYSIOLOGY; RANDOMIZATION; SUBSTANTIA NIGRA;

ANIMALS; ANTIPARKINSON AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BEHAVIOR, ANIMAL; BIOMARKERS; DIETARY SUPPLEMENTS; DOPAMINE; DOPAMINERGIC NEURONS; LUTEIN; MALE; MICE, INBRED C57BL; MITOCHONDRIA; MOTOR ACTIVITY; MPTP POISONING; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE; RANDOM ALLOCATION; SUBSTANTIA NIGRA;

EID: 84981244983     PISSN: 1028415X     EISSN: 14768305     Source Type: Journal    
DOI: 10.1179/1476830515Y.0000000010     Document Type: Article

References (51)

1. de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol 2006;5: 525-35.
2. Smeyne RJ, Jackson-Lewis V. The MPTP model of Parkinson’s disease. Brain Res Mol Brain Res 2005;134: 57-66.
3. Seo BB, Nakamaru-Ogiso E, Flotte TR, Matsuno-Yagi A, Yagi T. In vivo complementation of complex I by the yeast Ndi1 enzyme. Possible application for treatment of Parkinson disease. J Biol Chem 2006;281: 14250-5.
4. Park G, Park YJ, Yang HO, Oh MS. Ropinirole protects against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced neurotoxicity in mice via anti-apoptotic mechanism. Pharmacol Biochem Behav 2013;104: 163-8.
5. Anandhan A, Tamilselvam K, Radhiga T, Rao S, Essa MM, Manivasagam T. Theaflavin, a black tea polyphenol, protects nigral dopaminergic neurons against chronic MPTP/probenecid induced Parkinson’s disease. Brain Res 2012;1433: 104-13.
6. Selvakumar GP, Janakiraman U, Essa MM, Justin Thenmozhi A, Manivasagam T. Escin attenuates behavioral impairments, oxidative stress and inflammation in a chronic MPTP/probenecid mouse model of Parkinson’s disease. Brain Res 2014;20. doi: 10.1016/j.brainres.2014.03.010.
7. Sommerburg O, Keunen JE, Bird AC, van Kuijk FJ. Fruits and vegetables that are sources for lutein and zeaxanthin: the macular pigment in human eyes. Br J Ophthalmol 1998;82: 907-10.
8. Sasaki M, Ozawa Y, Kurihara T, Kubota S, Yuki K, Noda K, Kobayashi S, Ishida S, Tsubota K. Neurodegenerative influence of oxidative stress in the retina of a murine model of diabetes. Diabetologia 2010;53: 971-9.
9. Li SY, Lo AC. Lutein protects RGC-5 cells against hypoxia and oxidative stress. Int J Mol Sci 2010;11: 2109-17.
10. Li SY, Yang D, Fu ZJ, Woo T, Wong D, Lo ACY. Lutein enhances survival and reduces neuronal damage in a mouse model of ischemic stroke. Neurobiol Dis 2012;45: 624-32.
11. Jhonson EJ. Role of lutein and zeaxanthin in visual and cognitive function throughout the lifespan. Nutr Rev 2014; 1-8.
12. Akbaraly NT, Faure H, Gourlet V, Favier A, Berr C. Plasma carotenoid levels and cognitive performance in an elderly population: results of the EVA study. J Gerontol A Biol Sci Med Sci 2007;62: 308-16.
13. Binawade Y, Jagtap A. Neuroprotective effect of lutein against 3- nitropropionic acid-induced Huntington’s disease-like symptoms: possible behavioral, biochemical, and cellular alterations. J Med Food 2013;16: 934-43.
14. Anandhan A, Janakiraman U, Manivasagam T. Theaflavin ameliorates behavioral deficits, biochemical indices and monoamine transporters expression against subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of Parkinson’s disease. Neuroscience 2012b;218: 257-67.
15. Rajasankar S, Manivasagam T, Surendran S. Withania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson’s disease model mouse. J Ethnopharmacol 2009;125: 369-73.
16. Mohanasundari M, Srinivasan MS, Sethupathy S, Sabesan M. Enhanced neuroprotective effect by combination of bromocriptine and hypericum perforatumextract against MPTP-induced neurotoxicity in mice, J Neurol Sci 2006;249: 140-4.
17. Anandhan A, Essa MM, Manivasagam T. Therapeutic attenuation of neuroinflammation and apoptosis by black tea theaflavin in chronic MPTP/probencid model of Parkinson’s disease. Neurotox Res 2013;23: 166-73.
18. Franklin KBJ, Paxinos G. The mouse brain in stereotaxic coordinates. London: Academic Press, 2007.
19. Muralikrishnan D, Mohanakumar KP. Neuroprotection by bromocriptine against 1-methyl 4-phenyl 1,2,3,6 tetrahydropyridine induced neurotoxicity in mice. FASEB J 1998;12: 905-12.
20. Bhattacharya A, Ghosal S, Bhattacharya SK. Antioxidant effect of Withania somniferaglycowithanolides in chronic foot-shock stress-induced perturbations of oxidative free radical scavenging enzymes and lipid peroxidation in rat frontal cortex and striatum. J Ethnopharmacol 2001;74: 1-16.
21. Oberley LW, Spitz DR. Assay of superoxide dismutase activity in tumor tissue. Methods Enzymol 1984;105: 457-64.
22. Jollow DJ, Mitchell JR, Zampaglione N, Gillette JR. Bromobenzeneinduced liver necrosi. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology 1974;11: 151-69.
23. Yamamoto Y, Takahashi K. Glutathione peroxidase isolated from plasma, reduces phospholipid hydroperoxide. Arch Biochem Biophys 1993;305: 541-5.
24. Wright AM, Bempong J, Kirby ML, Barlow RL, Bloomquist JR. Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia. Brain Res 1998;788: 215-22.
25. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193: 265-75.
26. Koppula S, Kumar H, More SV, Lim HW, Hong SM, Choi DK. Recent updates in redox regulation and free radical scavenging effects by herbal products in experimental. Model Parkinson Dis Mole 2012;17: 11391-420.
27. Kavitha M, Nataraj J, Essa MM, Manivasagam T. Mangiferin attenuates MPTP induced dopaminergic neurodegeneration and improves motor impairment, redox balance and Bcl-2/Bax expression. Chem Biolo Interact 2013;206: 239-47.
28. Sriram K, Pai KS, Boyd MR, Ravindranath V. Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice. Brain Res 1997;749: 44-52.
29. Cecarini V, Gee J, Fioretti E, Amici M, Angeletti M, Eleuteri et al. Protein oxidation and cellular homeostasis: emphasis on metabolism. Biochim Biophys Acta 2007;1773: 93-104.
30. Cadenas E, Davies KJ. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 2000;29: 222-30.
31. Dhanasekaran M, Uthayathas S, Karuppagounder SS, Parameshwaran K, Suppiramaniam V, Ebadi M et al. Ebselen effects on MPTP-induced neurotoxicity. Brain Res 2006;1118: 251-4.
32. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD. Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem 1989; 52: 381-9.
33. Dexter DT, Holley AE, Flitter WD, Slater TF, Wells FR, Daniel SE et al. Increased levels of lipid hydroperoxides in the parkinsonia substania nigra: an HPLC and ESR study. Mov Disord 1994; 9: 92-97.
34. Ribaya-Mercado JD, Blumberg JB. Lutein and zeaxanthin and their potential roles in disease prevention. J Am Coll Nutr 2004;23: 567S-87S.
35. Li SY, Fu ZJ, Ma H, Jang WC, So KF, Wong D, Lo AC. Effect of lutein on retinal neurons and oxidative stress in a model of acute retinal ischemia/reperfusion. Invest Ophthalmol Vis Sci 2009;50: 836-43.
36. Chen X, Zhou Y, Chen Y, Zhu Y, Fang F, Chen L. Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress. Acta Pharmacol 2005;26: 56-62.
37. Genc S, Akhisaroglu M, Kuralay F, Genc K. Erythropoietin restores glutathione peroxidase activity in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced neurotoxicity in C57BL mice and stimulates murine astroglial glutathione peroxidase production in vitro. Neurosci Lett 2002;321: 73-76.
38. Perry TL, Godin DV, Hansen S. Parkinson’s disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 1982;33: 305-10.
39. Muriach M, Bosch-Morell F, Alexander G, Blomhoff R, Barcia J, Arnal E et al. Lutein effect on retina and hippocampus of diabetic mice. Free Radic Biol Med 2006;41: 979-84.
40. Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 2000;1: 120-9.
41. Mitchell IJ, Cooper AC, Griffiths MR, Cooper AJ. Acute administration of haloperidol induced apoptosis of neurons in the striatum and substantia nigra in the rat. Neuroscience 2002;109: 89-99.
42. Adams JM, Cory S. The bcl-2 family: arbiters of cell survival. Science 1998;28: 1322-6.
43. Lindsten T, ZongW, Thompson CB. Defining the role of the Bcl-2 family of proteins in the nervous system. Neuroscientist 2005; 11: 10-15.
44. Youdim MB, Arraf Z. Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Neuropharmacology 2004;46: 1130-40.
45. Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA et al. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson’s disease. Proc Natl Acad Sci USA 2000;97: 2875-80.
46. Viswanath V, Wu Y, Boonplueang R, Chen S, Stevenson FF, Yantiri F et al. Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson’s disease. J. Neurosci 2001;21: 9519-28.
47. Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 2003;348: 1365-75.
48. Chen JY, Hsu PC, Hsu IL, Yeh GC. Sequential up-regulation of the c-fos, cjun and bax genes in the cortex, striatum and cerebellum induced by a single injection of a low dose of 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP) in C57BL/6 mice. Neurosci Lett 2001;314: 49-52.
49. Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991;114: 2283-301.
50. Essa MM, Braidy N, Bridge W, Subash S, Manivasagam T, Vijayan RK, Al-Adawi S, Guillemin GJ. Review of natural products on Parkinson’s disease pathology. J Aging Res Clin Pract 2014;3(3): 127-36.
51. Royland JE, Langston JW. MPTP: a dopiminergic neurotoxin. In Highly selective neurotoxins: basic and clinical applications (R. Kostrezewa, ed.) 1998; 141-94. Totowa: Humana Press.